BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...
Amgen (NASDAQ: AMGN) today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London. Data ...
The FOURIER-OLE studies evaluated 6,635 patients from the FOURIER parent study (3,355 initially randomized to Repatha and 3,280 to placebo) from the U.S. and Europe. 1 The studies were designed to ...
The Repatha data evaluated all primary endpoint events from the patients enrolled in the parent FOURIER study (n=27,564), with a median follow up of 2.2 years, and for patients who received Repatha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results